10 Most Promising Biotech Stocks According to Analysts

Published on February 25, 2023 at 11:38 am by Hamna Asim in Hedge Funds, News

In this article, we discuss 10 most promising biotech stocks according to analysts. If you want to see more stocks in this selection, check out 5 Most Promising Biotech Stocks According to Analysts.

Last year was a period of transition for biotech firms. Following significant investment, the availability of cheap capital, and public recognition for companies developing COVID-19 treatments and vaccines, the initial public offering market stalled in 2022, and there was a reduction in the number of new drug approvals. As biotech companies plan for the remainder of this year, they must contend with ongoing uncertainty. Nevertheless, these challenges and uncertainties create several opportunities for well-funded companies.

It is expected that small private biotech firms will make a comeback in the initial public offering market in the later part of 2023 as the rate of interest rate hikes slows down. However, due to challenging economic conditions, investors are likely to be more selective in their choices and prioritize companies with drugs in human trials. After a successful year in 2021, the number of initial public offerings (IPOs) across all industries took a sharp decline worldwide in the past year. This decline was due to central banks’ implementation of aggressive interest rate hikes to combat inflation, thereby ending the period of easily available and low-cost capital. The biotech sector experienced a significant drop in initial public offerings in the last year, with only 47 IPOs that raised a total of roughly $4 billion. This was in contrast to 2021, where there were 152 IPOs that generated over $25 billion in funds.

A report by EY revealed that as of December 2022, biopharma companies held dealmaking capacity of over $1.4 trillion. This is due to the fact that pharmaceutical giants are facing the expiration of patents on their key drugs and are searching for new promising assets. Analysts have identified developmental obesity treatments, Alzheimer’s disease drugs, cell and gene therapies, and the breakthrough messenger-RNA technology as areas that are attracting investor interest. Sean Sun, portfolio manager at Thornburg Investment Management, said:

“Now we’re in this sweet spot where you’re seeing signs of disinflation, you’re seeing risk appetite improve. All we need is one or two biotech IPOs to get good interest and the floodgates will open.”

Investors can also check out 11 Most Undervalued Biotech Stocks, 12 Cheap Biotech Stocks To Buy, and 12 Best Biotech Stocks To Buy Under $10. Some of the top biotech stocks include Pfizer Inc. (NYSE:PFE), Amgen Inc. (NASDAQ:AMGN), and Intellia Therapeutics, Inc. (NASDAQ:NTLA).

Our Methodology

To determine the most promising biotech stocks, we focused on pure-play biotech companies. We narrowed down our selection to biotech stocks that had the highest upside potential based on average analyst price targets. We have ranked our picks in ascending order of their average upside potential, as of February 24.

Photo by National Cancer Institute on Unsplash

Most Promising Biotech Stocks According to Analysts

10. Legend Biotech Corporation (NASDAQ:LEGN)

Number of Hedge Fund Holders: 28

Average Upside Potential as of February 24: 57.48%

Legend Biotech Corporation (NASDAQ:LEGN) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. On January 27, Legend Biotech Corporation (NASDAQ:LEGN) made an announcement that its CAR-T cell therapy called Carvykti, which is co-developed with Johnson & Johnson (NYSE: JNJ), achieved the primary objective in a Phase 3 clinical trial for individuals suffering from multiple myeloma. Legend Biotech Corporation (NASDAQ:LEGN) plans to present the trial results at an upcoming medical conference and to discuss the findings with regulatory agencies in order to make submissions for approval.

On January 27, Edward Tenthoff, an analyst at Piper Sandler, reaffirmed his positive stance on Legend Biotech Corporation (NASDAQ:LEGN) by maintaining an Overweight rating and setting a $78 target price. This comes after the company’s announcement that its Phase 3 trial for Carvykti, a treatment for relapsed and lenalidomide-refractory multiple myeloma in adults, achieved its primary endpoint. Piper Sandler forecasts a significant growth of Carvykti’s sales by 157% to $344 million in 2023 and highlighted Janssen’s expectation of peak sales of $5 billion for Carvykti.

According to Insider Monkey’s data, 28 hedge funds were long Legend Biotech Corporation (NASDAQ:LEGN) at the end of Q4 2022, compared to 29 funds in the prior quarter. Lei Zhang’s Hillhouse Capital Management is the largest stakeholder of the company, with a position worth $256.4 million.

In addition to Pfizer Inc. (NYSE:PFE), Amgen Inc. (NASDAQ:AMGN), and Intellia Therapeutics, Inc. (NASDAQ:NTLA), Legend Biotech Corporation (NASDAQ:LEGN) is one of the prominent biotech plays to watch.

TimesSquare Capital made the following comment about Legend Biotech Corporation (NASDAQ:LEGN) in its Q3 2022 investor letter:

“New to the strategy this quarter is Legend Biotech Corporation (NASDAQ:LEGN), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications. The company’s lead product is a CAR-T treatment for multiple myeloma and is currently in joint development/commercialization with Janssen Biotech. Chimeric antigen receptor T cells are genetically engineered for use in immunotherapy.”

9. Moderna, Inc. (NASDAQ:MRNA)

Number of Hedge Fund Holders: 52

Average Upside Potential as of February 24: 58.97%

Moderna, Inc. (NASDAQ:MRNA) is a Massachusetts-based biotechnology company that discovers, develops, and markets messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. On February 23, Moderna, Inc. (NASDAQ:MRNA) reported a Q4 GAAP EPS of $3.61, missing estimates by $1.14. The revenue of $5.1 billion outperformed Wall Street consensus by $80 million.

On February 23, Morgan Stanley decreased its price target on Moderna, Inc. (NASDAQ:MRNA) to $185 from $205 due to higher expenses and capital expenditures, and maintained an Equal Weight rating on the company’s shares. Morgan Stanley reported that Moderna, Inc. (NASDAQ:MRNA)’s Q4 performance was generally consistent with expectations. However, the 2023 cost of goods sold estimate of 35%-40% exceeded expectations and was a significant downside factor in Morgan Stanley’s projections. On the other hand, the firm highlighted that potential early filings for PCV, launches of flu and RSV vaccines in 2024, and a stronger U.S. commercial COVID market could act as potential drivers for near-term growth.

According to Insider Monkey’s Q4 data, Moderna, Inc. (NASDAQ:MRNA) was part of 52 hedge fund portfolios, up from 44 in the prior quarter. Philippe Laffont’s Coatue Management is the biggest stakeholder of the company, with 6.3 million shares worth $1.14 billion.

ClearBridge Select Strategy made the following comment about Moderna, Inc. (NASDAQ:MRNA) in its Q4 2022 investor letter:

“Moderna, Inc. (NASDAQ:MRNA) became a household name during the pandemic as one of the first developers of a COVID-19 vaccine. But the stock sold off sharply as COVID momentum, including high expectations for booster shots, began to wear off, causing investors to slash its fiscal 2023 earnings estimates by two-thirds over the last year. We believe those downward revisions clouded the prospects for the company’s fully funded pipeline of platform opportunities, including cancer, RSV and flu. The cash-rich company also recently expanded its partnership with Merck to improve cancer treatments.”

8. Roivant Sciences Ltd. (NASDAQ:ROIV)

Number of Hedge Fund Holders: 35

Average Upside Potential as of February 24: 61.18%

Roivant Sciences Ltd. (NASDAQ:ROIV) is a London-based biopharmaceutical and healthcare technology company that develops product candidates for the treatment of solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. Roivant Sciences Ltd. (NASDAQ:ROIV) is one of the most promising biotech stocks as per Wall Street analysts.

On February 13, the company reported its Q4 earnings. The GAAP loss per share of $0.49 missed Street consensus by $0.09. Roivant Sciences Ltd. (NASDAQ:ROIV)’s revenue of $17.05 million exceeded estimates by $2.27 million. As of December 31, 2022, the company had cash, cash equivalents and restricted cash of approximately $1.5 billion.

Neena Bitritto-Garg, an analyst at Citi, increased the company’s price target on Roivant Sciences Ltd. (NASDAQ:ROIV) to $14 from $11 and has maintained a Buy rating on its shares on January 5.

According to Insider Monkey’s Q4 data, 35 hedge funds were long Roivant Sciences Ltd. (NASDAQ:ROIV), compared to 28 funds in the prior quarter. Daniel Gold’s QVT Financial is the largest investor in the company.

7. Beam Therapeutics Inc. (NASDAQ:BEAM)

Number of Hedge Fund Holders: 18

Average Upside Potential as of February 24: 61.78%

Beam Therapeutics Inc. (NASDAQ:BEAM) is a Massachusetts-based biotechnology company that develops precision genetic medicines for patients suffering from serious diseases in the United States. Beam Therapeutics Inc. (NASDAQ:BEAM) is one of the most promising biotech plays according to analysts, with an average upside potential of nearly 62% as of February 24.

On February 1, Rick Bienkowski, an analyst at Cantor Fitzgerald, started coverage of Beam Therapeutics Inc. (NASDAQ:BEAM) with an Overweight rating and a $62 price target. In a research note to investors, the analyst suggested that despite only recently commencing Phase 1 clinical trials for sickle cell disease, Beam Therapeutics Inc. (NASDAQ:BEAM)’s platform, pipeline, and ability to establish partnerships with advantageous economics offer long-term value. The firm also recognizes substantial scarcity value in Beam Therapeutics Inc. (NASDAQ:BEAM)’s base-editing technology and believes that partner Verve Therapeutics’ Phase 1 data presentation in 2H23 could confirm the validity of Beam’s base-editing platform and in vivo treatment approach.

According to Insider Monkey’s fourth quarter database, 18 hedge funds were bullish on Beam Therapeutics Inc. (NASDAQ:BEAM), compared to 27 funds in the preceding quarter. Cathie Wood’s ARK Investment Management is the biggest stakeholder of the company, with 8.2 million shares worth $321.2 million.

Here is what Baron Health Care Fund has to say about Beam Therapeutics Inc. (NASDAQ:BEAM) in their Q1 2021 investor letter:

“Beam Therapeutics Inc. is a biotechnology company pioneering a novel technology called base editing, which allows for individual base pairs (the letters of DNA) to be modified. Shares fell along with other biotechnology stocks driven by a sudden rise in treasury yields. Early stage biotechnology stocks are particularly sensitive to interest rates because their cash flows are further in the future. We believe we are entering into a phase of significant advancement for the gene editing field that will eventually lead to curative therapies, and we think Beam has a unique platform technology.”

6. CRISPR Therapeutics AG (NASDAQ:CRSP)

Number of Hedge Fund Holders: 28

Average Upside Potential as of February 24: 77.43%

CRISPR Therapeutics AG (NASDAQ:CRSP) is a gene editing company focused on developing gene-based medicines for serious diseases using its CRISPR-associated protein 9 (Cas9) platform. CRISPR Therapeutics AG (NASDAQ:CRSP) shares gained nearly 14% on February 22, the biggest intraday gain since January 2021, a day after the firm announced its Q4 2022 results with a corporate update.

On February 23, Oppenheimer maintained an Outperform rating on CRISPR Therapeutics AG (NASDAQ:CRSP) but reduced its price target on the shares to $102 from $110 following the release of the company’s Q4 results. The firm believes that the main focus this year will continue to be on the potential approval and commercial readiness of Exacel. According to recent disclosures, both the European Medicines Agency and the UK’s Medicines and Healthcare products Regulatory Agency have validated the Marketing Authorization Application submissions for exa-cel, and the rolling submissions to the US Food and Drug Administration are expected to be completed in the first quarter of 2023.

According to Insider Monkey’s Q4 data, 28 hedge funds were long CRISPR Therapeutics AG (NASDAQ:CRSP), compared to 29 funds in the prior quarter. Steven Boyd’s Armistice Capital is a prominent stakeholder of the company, with 1 million shares worth $42 million.

Like Pfizer Inc. (NYSE:PFE), Amgen Inc. (NASDAQ:AMGN), and Intellia Therapeutics, Inc. (NASDAQ:NTLA), elite hedge funds are piling into CRISPR Therapeutics AG (NASDAQ:CRSP) for exposure to the biotech sector.

Click to continue reading and see 5 Most Promising Biotech Stocks According to Analysts.

AI, Tariffs, Nuclear Power: One Undervalued Stock Connects ALL the Dots (Before It Explodes!)

Published on June 23, 2025 at by Inan Dogan, PhD

Artificial intelligence is the greatest investment opportunity of our lifetime. The time to invest in groundbreaking AI is now, and this stock is a steal!

AI is eating the world—and the machines behind it are ravenous.

Each ChatGPT query, each model update, each robotic breakthrough consumes massive amounts of energy. In fact, AI is already pushing global power grids to the brink.

Wall Street is pouring hundreds of billions into artificial intelligence—training smarter chatbots, automating industries, and building the digital future. But there’s one urgent question few are asking:

Where will all of that energy come from?

AI is the most electricity-hungry technology ever invented. Each data center powering large language models like ChatGPT consumes as much energy as a small city. And it’s about to get worse.

Even Sam Altman, the founder of OpenAI, issued a stark warning:

“The future of AI depends on an energy breakthrough.”

Elon Musk was even more blunt:

“AI will run out of electricity by next year.”

As the world chases faster, smarter machines, a hidden crisis is emerging behind the scenes. Power grids are strained. Electricity prices are rising. Utilities are scrambling to expand capacity.

And that’s where the real opportunity lies…

One little-known company—almost entirely overlooked by most AI investors—could be the ultimate backdoor play. It’s not a chipmaker. It’s not a cloud platform. But it might be the most important AI stock in the US owns critical energy infrastructure assets positioned to feed the coming AI energy spike.

As demand from AI data centers explodes, this company is gearing up to profit from the most valuable commodity in the digital age: electricity.

The “Toll Booth” Operator of the AI Energy Boom

It owns critical nuclear energy infrastructure assets, positioning it at the heart of America’s next-generation power strategy.
It’s one of the only global companies capable of executing large-scale, complex EPC (engineering, procurement, and construction) projects across oil, gas, renewable fuels, and industrial infrastructure.
It plays a pivotal role in U.S. LNG exportation—a sector about to explode under President Trump’s renewed “America First” energy doctrine.

Trump has made it clear: Europe and U.S. allies must buy American LNG.

And our company sits in the toll booth—collecting fees on every drop exported.

But that’s not all…

As Trump’s proposed tariffs push American manufacturers to bring their operations back home, this company will be first in line to rebuild, retrofit, and reengineer those facilities.

AI. Energy. Tariffs. Onshoring. This One Company Ties It All Together.

While the world is distracted by flashy AI tickers, a few smart investors are quietly scooping up shares of the one company powering it all from behind the scenes.

AI needs energy. Energy needs infrastructure.

And infrastructure needs a builder with experience, scale, and execution.

This company has its finger in every pie—and Wall Street is just starting to notice.

Wall Street is noticing this company also because it is quietly riding all of these tailwinds—without the sky-high valuation.

While most energy and utility firms are buried under mountains of debt and coughing up hefty interest payments just to appease bondholders…

This company is completely debt-free.

In fact, it’s sitting on a war chest of cash—equal to nearly one-third of its entire market cap.

It also owns a huge equity stake in another red-hot AI play, giving investors indirect exposure to multiple AI growth engines without paying a premium.

And here’s what the smart money has started whispering…

The Hedge Fund Secret That’s Starting to Leak Out

This stock is so off-the-radar, so absurdly undervalued, that some of the most secretive hedge fund managers in the world have begun pitching it at closed-door investment summits.

They’re sharing it quietly, away from the cameras, to rooms full of ultra-wealthy clients.

Why? Because excluding cash and investments, this company is trading at less than 7 times earnings.

And that’s for a business tied to:

The AI infrastructure supercycle
The onshoring boom driven by Trump-era tariffs
A surge in U.S. LNG exports
And a unique footprint in nuclear energy—the future of clean, reliable power

You simply won’t find another AI and energy stock this cheap… with this much upside.

This isn’t a hype stock. It’s not riding on hope.

It’s delivering real cash flows, owns critical infrastructure, and holds stakes in other major growth stories.

This is your chance to get in before the rockets take off!

Disruption is the New Name of the Game: Let’s face it, complacency breeds stagnation.

AI is the ultimate disruptor, and it’s shaking the foundations of traditional industries.

The companies that embrace AI will thrive, while the dinosaurs clinging to outdated methods will be left in the dust.

As an investor, you want to be on the side of the winners, and AI is the winning ticket.

The Talent Pool is Overflowing: The world’s brightest minds are flocking to AI.

From computer scientists to mathematicians, the next generation of innovators is pouring its energy into this field.

This influx of talent guarantees a constant stream of groundbreaking ideas and rapid advancements.

By investing in AI, you’re essentially backing the future.

The future is powered by artificial intelligence, and the time to invest is NOW.

Don’t be a spectator in this technological revolution.

Dive into the AI gold rush and watch your portfolio soar alongside the brightest minds of our generation.

This isn’t just about making money – it’s about being part of the future.

So, buckle up and get ready for the ride of your investment life!

Act Now and Unlock a Potential 100+% Return within 12 to 24 months.

We’re now offering month-to-month subscriptions with no commitments.

For a ridiculously low price of just $9.99 per month, you can unlock our in-depth investment research and exclusive insights – that’s less than a single fast food meal!

Here’s why this is a deal you can’t afford to pass up:

Access to our Detailed Report on our AI, Tariffs, and Nuclear Energy Stock with 100+% potential upside within 12 to 24 months
BONUS REPORT on our #1 AI-Robotics Stock with 10000% upside potential: Our in-depth report dives deep into our #1 AI/robotics stock’s groundbreaking technology and massive growth potential.
One New Issue of Our Premium Readership Newsletter: You will also receive one new issue per month and at least one new stock pick per month from our monthly newsletter’s portfolio over the next 12 months. These stocks are handpicked by our research director, Dr. Inan Dogan.
One free upcoming issue of our 70+ page Quarterly Newsletter: A value of $149
Bonus Content: Premium access to members-only fund manager video interviews
Ad-Free Browsing: Enjoy a month of investment research free from distracting banner and pop-up ads, allowing you to focus on uncovering the next big opportunity.
Lifetime Price Guarantee: Your renewal rate will always remain the same as long as your subscription is active.
30-Day Money-Back Guarantee: If you’re not absolutely satisfied with our service, we’ll provide a full refund within 30 days, no questions asked.

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

1. Head over to our website and subscribe to our Premium Readership Newsletter for just $9.99.

2. Enjoy a month of ad-free browsing, exclusive access to our in-depth report on the Trump tariff and nuclear energy company as well as the revolutionary AI-robotics company, and the upcoming issues of our Premium Readership Newsletter.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

Subscribe Now!

No worries about auto-renewals! Our 30-Day Money-Back Guarantee applies whether you’re joining us for the first time or renewing your subscription a month later!

Insider Monkey Ads

A New Dawn is Coming to U.S. Stocks

Published on June 13, 2025 at by Insider Monkey Staff

I work for one of the largest independent financial publishers in the world – representing over 1 million people in 148 countries.

We’re independently funding today’s broadcast to address something on the mind of every investor in America right now…

Should I put my money in Artificial Intelligence?

Here to answer that for us… and give away his No. 1 free AI recommendation… is 50-year Wall Street titan, Marc Chaikin.

Marc’s been a trader, stockbroker, and analyst. He was the head of the options department at a major brokerage firm and is a sought-after expert for CNBC, Fox Business, Barron’s, and Yahoo! Finance…

But what Marc’s most known for is his award-winning stock-rating system. Which determines whether a stock could shoot sky-high in the next three to six months… or come crashing down.

That’s why Marc’s work appears in every Bloomberg and Reuters terminal on the planet…

And is still used by hundreds of banks, hedge funds, and brokerages to track the billions of dollars flowing in and out of stocks each day.

He’s used this system to survive nine bear markets… create three new indices for the Nasdaq… and even predict the brutal bear market of 2022, 90 days in advance.

Click to continue reading…

Insider Monkey Ads

Markets

Insider Trading

Hedge Funds

Retirement

Opinion

Log In

Sign Up